
Sign up to save your podcasts
Or


As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn’s disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.
As the advanced treatment landscape for irritable bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn’s disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.
When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn’s disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.
Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.
Topical hemostatic agents play a key role in managing complex bleeding cases, but there’s a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.
While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.
For many patients with Crohn’s disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn’s and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.
For patients with Crohn’s disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
Recent changes to the American College of Gastroenterology’s guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.
From the publisher's feed

135 Listeners

69 Listeners

1 Listeners

3 Listeners

3 Listeners

0 Listeners

6 Listeners

15 Listeners

0 Listeners

3,343 Listeners